[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IFOM ETS - The AIRC Institute of Molecular Oncology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,70,94,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100553780","phase-3-the-sagittarius-trial-100553780",false,"NCT06490536","The Sagittarius Trial","A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients","Inclusion Criteria:\n\n* SAGITTARIUS trial written informed consent.\n* Age ≥ 18 years.\n* Histologically confirmed diagnosis of operable stage III and High-Risk stage II CC located at least 12 cm from the anal verge by endoscopy and above the peritoneal reflection at surgery.\n* Availability of the original FFPE tumor tissue.\n* ECOG performance status 0-1.\n* Normal organ functions (as defined in section 9.3).\n* Women with childbearing potential (WOCBP) should complete a pregnancy test and be willing to use highly effective contraceptive methods.\n\nExclusion Criteria:\n\n* History of another neoplastic disease, unless in remission for ≥ 5 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n* Macroscopic or microscopic evidence of residual tumor (R1 or R2 resections). Patients should never have had any evidence of metastatic disease (including presence of tumor cells in the peritoneal lavage).\n* Current or recent treatment with another investigational drug or participation in another investigational study.\n* Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.\n* Inadequate contraception (male or female patients) if of childbearing or procreational potential.\n* Clinically relevant cardiovascular disease.\n* Acute or subacute intestinal occlusion or history of inflammatory bowel disease or any other autoimmune disease.\n* Pre-existing neuropathy \\> grade 1. Known grade 3 or 4 allergic reaction to any of the components of the treatment.\n* Has a known history of Human Immunodeficiency Virus (HIV).\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus infection.\n* Has a known history of active TB (Bacillus Tuberculosis).\n* Has a medical condition that contraindicate the use of the investigational medicinal product (IMP) according to product indications.\n* Prior neoadjuvant treatment administered before surgery.","ALL","18 Years",{"count":19,"type":20},700,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Background \\& Rationale:\n\nColon cancer is a leading cause of cancer deaths, with a high recurrence rate in stage II high-risk and stage III patients due to undetectable micro-metastases. Liquid biopsy (LB) detects residual cancer DNA post-surgery and monitors treatment response.\n\nPrimary Objective:\n\nShow that therapy based on tumor genetics and LB improves outcomes and quality of life for high-risk stage II and stage III colon cancer patients compared to conventional therapy.\n\nSecondary Objectives:\n\nCompare recurrence times. Evaluate side effects and quality of life. Assess cost differences. Validate LB accuracy.\n\nStudy Design: Patients are randomized into standard or personalized treatment groups based on LB results.\n\nFor positive LB results:\n\nRandomized to standard or customized therapy. Monitor treatment response with LB.\n\nFor negative LB results:\n\nRandomized to standard chemotherapy or follow-ups, starting treatment if a positive result appears.\n\nTreatments:\n\nStandard Chemotherapy:\n\nCAPOX (capecitabine and oxaliplatin) FOLFOX (folinic acid, fluorouracil, and oxaliplatin)\n\nPersonalized Treatments:\n\nCustomized chemotherapy with CAPOX. Immunotherapy with nivolumab and ipilimumab. Targeted therapy with trastuzumab and pertuzumab. FOLFOX with anti-EGFR (epidermal growth factor receptor) therapy (panitumumab).\n\nPopulation: 700 patients with operable stage III and high-risk stage II colon cancer.\n\nInclusion Criteria:\n\nAged 18 or older. Confirmed diagnosis. Tumor tissue sample available.\n\nExclusion Criteria:\n\nHistory of other tumors within five years. Metastatic disease or recent experimental study participation. Major cardiovascular diseases, intestinal obstruction, autoimmune diseases, neuropathy, HIV (Human Immunodeficiency Virus), active TB (Tuberculosis), or hepatitis B\u002FC infection.\n\nMedical conditions contraindicating treatment. Prior neoadjuvant treatment administered before surgery.\n\nEndpoints:\n\nPrimary:\n\nEvaluate disease recurrence after two years.\n\nSecondary:\n\nAssess disease recurrence and overall survival at 3 and 5 years. Measure treatment safety and tolerability. Validate LB accuracy. Monitor quality of life using questionnaires.\n\nThe study will last 5 years and be conducted in 25-30 hospitals across Italy, Spain, and Germany.",[26,27],"Colon Cancer Stage II","Colon Cancer Stage III","RECRUITING","2025-08-22",{"date":31,"type":32},"2025-08-29","ACTUAL",{"date":34,"type":32},"2024-10-22",{"date":36,"type":20},"2028-09-01",{"name":38,"class":39},"IFOM ETS - The AIRC Institute of Molecular Oncology","OTHER",26,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100484015","phase-2-restoring-sensitivity-to-immunotherapy-in-advanced-triple-negative-breast-cancer-exploiting-ceralasertib-priming-followed-by-combined-durvalumabnab-paclitaxel-100484015","NCT05582538","Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab\u002FNab-Paclitaxel","Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab\u002FNab-Paclitaxel: The ATRiBRAVE Trial","ATRiBRAVE","Inclusion Criteria:\n\n1. ATRiBRAVE trial written informed consent, prior to any study specific procedures\n2. Age ≥18 years old\n3. Ability to comply with the study protocol in the investigator's judgment.\n4. Ability to swallow and retain oral medication\n5. Availability of a formalin-fixed, paraffin-embedded block (FFPE) containing primary tumor tissue or at least 10-20 unstained tumor slides\n6. Metastatic TNBC patients who have not received prior systemic cytotoxic therapy in the advanced setting and whose tumor have relapsed from treatment with curative intent for early disease, which must have included ICI and chemotherapy as part of radical locoregional therapy\n7. Documented disease progression (e.g., with biopsy sample, pathology or imaging report) since the last treatment in the early setting with curative intent (neo\u002Fadjuvant regimen)\n8. Negative ER\u002FPgR (defined as \\\u003C10% of tumor cells expressing ER and PgR hormonal receptors) and HER2 status (HER2 IHC score 0, 1+ or 2+ non-amplified by in situ hybridization) must be confirmed in the most recent tumor sample (primary and\u002For metastatic)\n9. Evaluable disease, as defined by RECIST 1.1\n10. ECOG performance status 0-1 (refer to Appendix 1)\n11. Patients must have a life expectancy ≥ 3 months from proposed first dose date.\n12. Patients must have acceptable bone marrow, liver and renal functions measured within 28 days prior to administration of study treatment\n13. Body weight \\> 30kg\n14. Women with childbearing potential should complete a pregnancy test with negative result within 28 days of study treatment and be willing to use effective contraceptive methods from screening to 90 days after the last dose of durvalumab\n15. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm from screening to 90 days after the last dose of durvalumab.\n\nExclusion Criteria:\n\n1. Diagnosis of ataxia telangiectasia.\n2. Any previous treatment with ATR inhibitors, DNA-damage repair inhibitors.\n3. Patients, who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4 therapy:\n\n   1. Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n   2. All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.\n   3. Must not have experienced a ≥ Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of ≤ Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.\n   4. Must not have required the use of additional immunosuppression other than corticosteroids infliximab or Cellcept for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of \\> 10 mg prednisone or equivalent per day.\n4. Treatment with any investigational product during the last 28 days before the enrollment.\n5. Patients must have had a washout period of 3 weeks for any prior cancer therapy prior to the start of study drug. The following intervals between the end of the prior treatment and first dose of study drug must be observed: ≥ 4 weeks for radiotherapy (patients who receive palliative radiation for nontarget lesions need not have a 4 week washout period and can be enrolled immediately); patients may receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study; ≥ 4 weeks for major surgery; ≥ 7 days for minor surgical procedures; ≥ 14 days (or 5 half-lives whoever is longest) for any investigational product.\n6. Current or prior use of immunosuppressive medication within 4 weeks prior to the first dose of durvalumab, with the exceptions of intranasal, topical, inhaled corticosteroids, and systemic corticosteroids ≤ 10 mg prednisone \u002F day or equivalent.\n7. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, or other solid tumours curatively treated with no evidence of disease for ≤3 years.\n8. Any gastrointestinal condition that would preclude adequate absorption of ceralasertib, including but not limited to inability to swallow oral medication, refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection, intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment.\n9. Active or prior documented autoimmune or inflammatory disorders (including IBD \\[e.g. Crohn's disease, ulcerative colitis or diverticulitis\\], SLE, sarcoidosis syndrome, tuberculosis, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, history of primary immunodeficiency or HIV infection, known hepatitis B or hepatitis C infection, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis within the past 2 years prior to the start of treatment. The following are exceptions to this criterion: i) Subjects with vitiligo or alopecia; ii) hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; iii) any chronic skin condition that does not require systemic therapy; iv) patients with coeliac disease controlled by diet alone and patients without active disease in the last 5 years may be included but only after consultation with the study physician.\n10. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HbsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n11. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n12. Receipt of a live, attenuated vaccine within 30 days prior to the first dose of study treatment.\n13. Patients with confirmed COVID-19 infection by PCR test who have not made a full recovery\n14. History of allogeneic organ transplantation.\n15. Untreated central nervous system (CNS) metastatic disease or cord compression. Note: Patients with asymptomatic central nervous system (CNS) metastases are eligible, provided that all of the following criteria are met: (a) The metastases are limited to the supratentorial region or cerebellum (i.e., no metastases to midbrain, pons, medulla, or spinal cord are allowed); (b) No ongoing requirement for corticosteroids as therapy for CNS disease; (c) No stereotactic radiation within 7 days or whole-brain radiation or neurosurgical resection within 2 weeks before the start of study treatment; (d) Radiographic demonstration of interim stability (i.e., no progression) between the completion of CNS-directed therapy and the screening imaging study\n16. History of leptomeningeal disease\n17. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia or vitiligo\n18. Resting ECG with measurable QTcF \\> 470 msec on 2 or more time points within a 24-hour period or family history of long QT syndrome.\n19. Patients with cardiac problem as follows: uncontrolled hypertension or hypotension (BP ≥150\u002F95 mmHg despite medical therapy, BP \\\u003C90\u002F60 mmHg or orthostatic hypotension fall in BP \\>20 mmHg), Left ventricular ejection fraction \\\u003C55% measured by echocardiography, Atrial fibrillation with a ventricular rate \\>100 bpm on ECG at rest or any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block , third degree heart block, second degree heart block), Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy, Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to starting treatment.\n20. Stroke or transient ischemic attack in the last 6 months prior to screening.\n21. Uncontrolled symptomatic pleural effusion, pericardial effusion, or ascites.\n22. Uncontrolled hypercalcemia (\\> 1.5 mmol\u002FL ionized calcium or calcium \\> 12 mg\u002FdL or corrected serum calcium \\> ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy.\n23. Severe infection within 4 weeks prior to the first dose of study treatment (Cycle 1, Day 1), including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.\n24. Treatment with oral or IV antibiotics within 2 weeks prior to initiation of study treatment (Cycle 1, Day 1).\n25. Patients receiving routine antibiotic prophylaxis (e.g., to prevent chronic obstructive pulmonary disease exacerbation, urinary tract infection or for dental extraction) are eligible.\n26. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases that places the patient at unacceptable risk of toxicity or non-compliance. Examples include, but are not limited to, diabetes type I and II, active bleeding diatheses, renal transplant, uncontrolled seizures, severe COPD, superior vena cava syndrome, extensive bilateral lung disease on High Resolution CT scan, severe Parkinson's disease, refractory nausea or vomiting, irritable bowel syndrome, chronic gastrointestinal disease, significant bowel resection, psychiatric condition, or active infection including any patient known to have tuberculosis, hepatitis B, hepatitis C and human immunodeficiency virus (HIV) or requiring systemic antibiotics, antifungals or antiviral drugs. Screening for chronic conditions is not required.\n27. Concomitant use of known potent cytochrome P (CYP) 3A inhibitors (e.g., ketoconazole,itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir). The required washout period prior to starting study treatment is 2 weeks.\n28. Concomitant use of known strong CYP3A inducers (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\n29. Receiving or having received, concomitant medications, herbal supplements, and\u002For foods that significantly modulate Pgp activity (washout periods of 5 half-lives).\n30. Known hypersensitivity to ceralasertib, durvalumab or nab-paclitaxel or any of their excipients",{"count":50,"type":20},37,[52],"PHASE2","This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor relapsed following treatment with curative intent for early disease, which must have included immunotherapy and chemotherapy as part of the radical locoregional therapy (either adjuvant, neoadjuvant or both).",[55],"Triple Negative Breast Cancer Metastatic",[57,58,59,60,61],"immunotherapy","ATR inhibition","ceralasertib","durvalumab","nab-paclitaxel",{"date":63,"type":32},"2025-08-24",{"date":65,"type":32},"2022-12-15",{"date":67,"type":20},"2029-12",{"name":38,"class":39},6,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100447049","a-retrospective-protocol-empowering-precision-research-in-colorectal-cancer-alfaomega-retr-100447049","NCT05101382","A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)","ALFAOMEGA-R","Inclusion Criteria:\n\n* Histologically-confirmed diagnosis of colorectal cancer (any stage).\n* Age \\>18 years at the time of diagnosis.\n* Availability of clinically-annotated radio-imaging data and\u002For diagnostic Formalin-Fixed Paraffin Embedded (FFPE) blocks (surgical resections and\u002For tumor biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.\n* Verification that the patient could not be reached for informed consent in accordance with applicable national regulations.\n\nExclusion Criteria:\n\n* if inclusion criteria are not met",{"count":78,"type":20},500,"OBSERVATIONAL","ALFAOMEGA-RETRÒ will be exploited to retrospectively collect clinical and imaging data and archival samples to be used for validation and correlative studies on markers discovered by cutting-edge translational projects within the AIRC5x1000 program \"Insights into the evolving heterogeneity of colorectal cancer (CRC): from mechanism to therapies\" (an ongoing multi-institutional research program).",[82],"Colorectal Cancer",[84,85,86],"colorectal cancer","CRC","Gastrointestinal disease",{"date":63,"type":32},{"date":89,"type":32},"2020-10-28",{"date":91,"type":20},"2026-12",{"name":38,"class":39},13,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":111},"100371788","alfaomega-master-observational-trial-100371788","NCT04120935","ALFAOMEGA Master Observational Trial","A Master Protocol Empowering Precision Research in Colorectal Cancer","ALFAOMEGA","Inclusion Criteria:\n\n1. TIER1 written Informed consent.\n2. Patients ≥18 years of age.\n3. Previous diagnosis of colorectal cancer, or a strong suspicion of CRC based on clinical and radiological findings.\n4. In patients with previous diagnosis of CRC availability of diagnostic Formalin-Fixed, Paraffin Embedded (FFPE) blocks (surgical resection and\u002For tumor biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.\n5. ECOG Performance status \\\u003C 2.\n\nExclusion Criteria:\n\n1. Any other current malignancy or malignancy diagnosed or relapsed within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer)\n2. Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.\n3. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection.",{"count":103,"type":20},3000,"AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of CRC patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improval). This clinical resource for integrative clinical data and sample collection will allow the molecular story-telling of CRC metastatic spread along time and space and the selection of appropriate patients for experimentally-driven trials.",[82],{"date":63,"type":32},{"date":108,"type":32},"2019-10-15",{"date":91,"type":20},{"name":38,"class":39},19,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":130,"locationsCount":131},"100410477","a-master-protocol-empowering-mechanobiology-translation-research-in-breast-cancer-100410477","NCT04625023","A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer","METAMECH","Inclusion Criteria:\n\n1. Verification that the patient could not be reached for informed consent in accordance with applicable national regulations or, alternatively, TIER1 written Informed consent.\n2. Patients ≥18 years of age.\n3. Previous diagnosis of breast cancer, or a strong suspicion of BC based on clinical and radiological findings.\n4. ECOG Performance status \\\u003C 2 (only for TIER1-2).\n\nExclusion Criteria:\n\n1. Any other current malignancy or malignancy diagnosed or relapsed within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer)\n2. Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.\n3. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection.",{"count":120,"type":20},1500,"METAMECH is a master observational protocol designed to empower a bi-directional collaboration between basic and clinical research, an essential prerequisite to feed and implement precision oncology.\n\nMETAMECH will follow a stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years. Patients will be longitudinally sampled and matched clinical data (including imaging) will be collected. Via a multi-tiered informed consensus process, METAMECH will also allow to develop companion diagnostics for molecular enrichment strategies in AIRC-driven proof-of-concept trials.",[123],"Breast Cancer","2025-04-29",{"date":126,"type":32},"2025-05-01",{"date":128,"type":32},"2020-07-16",{"date":91,"type":20},{"name":38,"class":39},10,""]